Journal of Oncology Pharmacy Practice

Article	Citations
Alectinib continuation during COVID 19 ‘antiviral’ treatment: Risk or benefit?	29
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers	26
Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice	22
Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients	20
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant	14
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)	12
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer	12
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors	12
A room of errors simulation to improve pharmacy operators’ knowledge of cytotoxic drug production	12
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer	12
Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center	11
Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient	11
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients	11
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”	10
Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer	10
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma	10
Post COVID availability of oncology drugs – Is this the new normal on both sides of the Atlantic?	10
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities	10
Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions	10
Pharmacists’ practices and views regarding management of sexual health in patients with cancer	10
Initial real-world experience with ribociclib in advanced breast cancer	9
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies	9
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy	9
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients	9
Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review	8

Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products	8
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia	8
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer	8
Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases	8
Use of two general-purpose scales to assess clinical pharmacy activities in a cell transplantation unit	8
Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review	8
Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy	8
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma	8
Evaluating aggressiveness of end-of-life care in patients with advanced cancer: A retrospective single-center analysis	8
CAPhO Conference 2024 Abstract Book	8
Evaluation of voriconazole related adverse events in pediatric patients with hematological malignancies	8
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant	7
Assessment of chemical contamination by cancer drugs during use of the RIVATM compounding robot: A pilot study	7
Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches	7
Use of long-term corticosteroids in patients treated with CAR T-cell therapy	7
Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners	7
Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis	7
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia	7
Expanding oncology pharmacist teams: Justifying the return on investment	7
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review	7
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions	7
Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant	7
Nivolumab–ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment	7
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective	7
Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin	7
Continuous versus intermittent tacrolimus for graft-versus-host disease prophylaxis in pediatric hematopoietic stem cell transplantation patients (Tic Tac)	6
Assessment of adverse events among cervical cancer patients at Kenyatta National Hospital	6
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly	6
Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer	6
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant	6
Evaluation of potential drug-drug interactions in cancer patients at a tertiary care hospital in Pakistan	6
Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma	6
Belantamab mafodotin for relapsed or refractory multiple myeloma	6
Medical marijuana in the treatment of cancer-associated symptoms	6
Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non-small-cell lung cancer	6
Carfilzomib-induced thrombotic microangiopathy. A case report	6
Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff	6
Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients	6
Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer	6
Retrospective analysis of mortality within 30 days of systemic anticancer therapy and comparison with a previous audit at an Australian Regional Cancer Centre	6
A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient	6
Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment	6
The inpatient oncology pharmacist experience in the era of temporary oncologists	6
Capecitabine-related neurotoxicity presenting with agraphia	6
Gemcitabine-associated DRESS syndrome: A case report	6
ISOPP Standards for the Safe Handling of Cytotoxics	6
Inpatient utilization of immune checkpoint inhibitors and clinical outcomes	6
Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions	6
What are the competency requirements for clinical pharmacist verification of systemic anti-cancer therapy (SACT) prescribed within a clinical trial? A consensus study	6
Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia	6

Oral oncolytic monitoring pilot with patient-reported outcomes and adherence assessments	6
Preservation of cognitive function after brain irradiation	6
QTc prolongation during levofloxacin and triazole combination chemoprophylaxis: Prevalence and predisposing risk factors in a cohort of hematopoietic cell transplantation recipients	6
Erratum to Evaluation of antibiotic appropriateness at an outpatient oncology centre	5
Investigating effective methods of clinical pharmacy training on oncology for community pharmacists: An observational study	5
Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences	5
Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?	5
A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”	5
Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option	5
Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase	5
Rasburicase induced methemoglobinemia: A systematic review of descriptive studies	5
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review	5
Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)	5
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer	5
Hypersensitivity reaction to Abiraterone, successful desensitization protocol in prostate cancer patient	5
Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide	5
Retrospective study on the efficacy and tolerability of dose modification of PD-1 and PD-L1 inhibitors in hospital-system community outpatient cancer clinics	5
Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome	5
Pembrolizumab related perforated appendicitis	5
Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?	5
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma	5
Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center	5
Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies	5
Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis	5
Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients	5
Anti-cancer drug waste disposal practices and wastewater management in hospitals: A Lebanese survey	5
Characteristics of the clinical pharmacist interventions at the National Center for Cancer Care and Research Hospital in Qatar	5
Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution	5
Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series	5
Hepatic sinusoidal congestion associated with inotuzumab therapy in patients with B-cell acute lymphoblastic leukemia, a proposal for a new clinical entity: Calicheamicin syndrome	5
Rapid drug desensitization to taxanes: a descriptive study from Turkey	5
Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease	5
Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies	5
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer	5
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy	5
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemothera	5
Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions	5
Single center evaluation on the use of conditionally ordered low molecular weight heparins in malignant hematology patients with venous thromboembolism	4
Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience	4
Cancer procoagulant inhibitors: New drugs for an old target	4
Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer care hospital	4
Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study	4
Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion	4
A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population	4
An assessment of the prevalence of drug therapy problems and its associated factors among ovarian cancer patients at Kenyatta National Hospital	4
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review	4
Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient	4
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab	4
Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices	4
Carboplatin dosing in obese patients	4
Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study	4
Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions	4
Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report	4
Pharmacy practitioners’ adherence to safe-handling practices of chemotherapeutic drugs: A cross-sectional study in Saudi Arabia	4
Medication errors in an oncology inpatient setting in India—Audit by clinical pharmacists	4
Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient	4
Cabozantinib-induced heart failure	4
Gefitinib induced Pemphigus Vulgaris with PRIDE complex	4
Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’	4
Cytotoxic surface contamination in hospitals: Current practices, challenges and perspectives	4
Bilateral epithelial keratopathy and punctate keratitis due to ribociclib	4
Safe handling of hazardous drugs	4
Imatinib mesylate-induced acute hepatotoxicity	4
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R	4
Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial	4
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy	4
Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient	4
Retrospective drug utilization review of meropenem and role of infectious disease pharmacist in specialized cancer care hospital	4
A case of palmar-plantar erythrodysesthesia in a lung cancer patient receiving atezolizumab maintenance	4
Perceptions and prevalence of marijuana use among cancer patients managed at an outpatient department in Zimbabwe: A brief report	4
Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer	4
Automated chemotherapy compounding: Process optimization for the preparation of admixture containing high-dose of cyclophosphamide	4
Hand-foot syndrome and nail disorders secondary to treatment with paclitaxel: Is there a relationship with the presence of fungi?	4
The association between patient satisfaction with information and adherence to oral anticancer agents	4
Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update	4
Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents	4
Real-world experience of abemaciclib for adjuvant and metastatic breast cancer	4
Late side effects of cancer treatment in childhood cancer survivors	4
Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme	4
A prospective analysis of efficacy of dexamethasone-sparing antiemetic regimens in high and moderate emetogenic chemotherapy	4

Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab	4
Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipients	4
Examining clinical pharmacist interventions and identifying opioid medication-related issues in patients with cancer	4
Residual contamination in antineoplastic drug packaging	4
Panitumumab Associated Acute Pancreatitis	4
The role of the pharmacist in the hospital discharge of cancer patients: an integrative review	4
Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center	3
Advancements in the use of nanopharmaceuticals for cancer treatment	3
Trastuzumab-emtansine induced pleural and pericardial effusions	3
Vinorelbine-related tetraplegia due to severe peripheral neuropathy	3
Impact of telephone follow-up on hepatocellular carcinoma patients receiving oral chemotherapy from an ambulatory-care setting	3
Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer	3
Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide	3
Effects of scalp lotion containing alpha lipoic acid derivatives for chemotherapy-induced alopecia in patients with gastrointestinal cancer: A prospective cohort study	3
Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs	3
Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?	3
Evaluation of awareness about importance of high fever in leukemia and lymphoma patients receiving chemotherapy among healthcare professionals working in pharmacies other than hospital pharmacies: A s	3
Implementation of pharmaceutical care service to elderly cancer patients in a tertiary care hospital in South India	3
Stability study of concentrate-solvent mixture & infusion solutions of Jevtana® cabazitaxel for extended multi-dosing	3
The regulatory saga of fedratinib	3
Tamoxifen induced maculopathy presenting like macular telangiectasia type 2 in a patient with breast cancer	3
Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case	3
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome	3
Midostaurin-Associated acute pancreatitis	3
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units	3
Drug extravasation with Enfortumab vedotin	3
Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel	3
Factors affecting medication adherence in patients using oral chemotherapy: A descriptive study	3
Assessment of potential drug–drug interactions in hospitalized cancer patients	3
Preparations of exploration of immediate hypersensitivity to antineoplastic agents: An oncology pharmacy perspective	3
Retrospective assessment of chemotherapy/biotherapy toxicity in a Hispanic/Latinx population versus published study population	3
Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study	3
Implementation of Partnered Pharmacist Medication Charting in haematology and oncology inpatients	3
Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center	3
Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data	3
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia	3
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey	3
Role of Ketamine and Opioid Rotation in the Management of Opioid Induced Hyperalgesia in a Patient With Acute Promyelocytic Leukemia	3
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer	3
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations	3
Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate	3
Cycle-dependent eosinophilia due to adjuvant nivolumab for malignant melanoma	3
Pharmacist interventions in optimising opioid medication therapy in pain management for palliative care patients: A systematic review	3
Oncology pharmacy staffing survey across practice settings in the United States	3
Oncology boot camp: A preparatory curriculum for advanced pharmacy practice experience students	3
Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma	3
Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort	3
Workflow evaluation of environmental contamination with hazardous drugs during compounding and administration in an UK hospital	3
Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review	3
Factors associated with potentially inappropriate medications in elderly with multiple myeloma	3
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases	3
Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab	3
Re-use of erlotinib in a patient using osimertinib after erlotinib, case report	3
Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma	3
Redispensing of expensive oral anticancer medicines: A practical application	3
Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer	3
Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient	3
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma	3
Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study	3
Optimizing antimicrobial prophylaxis strategies in acute leukemia patients: Assessing the efficacy of fluconazole	3
The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis	3
Defining cytotoxic drugs – you know it when you see it?	3
Clinical pharmaceutical screening in critical situations in a radioiodine therapy management service	3
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers	3
A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country	3
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis	3
New-onset persistent hyperglycemia with initiation of brentuximab treatment	3
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer	3
Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis	3
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma	3
Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report	3
Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report	3
Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics	3
A study to quantify knowledge obtained during the British Oncology Pharmacy Association (BOPA) Introduction to Oncology (ITO) Course	3
Patterns and predictors of antidepressant prescribing among adults with cancer and depression in ambulatory care settings in the United States	3
Reduced emergency room visits and improved medication adherence of an integrated oncology pharmaceutical care practice in China	3
The effect of examining somatic alterations with NGS in patients with solid tumors, on patient management: A single-center experience in Turkey	3
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma	3
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review	3
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation	3
Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis	3
Optimizing intermittent dosing of oral small molecule inhibitors	3
Enhancing access to expensive oncology medications in Pakistan: The critical role of pharmaceutical patient assistance programs in oncology care	3
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method	3
A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study	3
Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia	3
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review	3
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring	3
A critical appraisal of South African oncology pharmacy standards: A comparison with international best practice standards	3
Development and use of an innovative Gap Finding Tool to create a Pharmaceutical Care Model within a paediatric oncology setting	3
Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia	3
Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity	2
Assessment of the surface contamination of the primary packaging of oral antineoplastic drugs and secondary packaging of chemotherapy preparations at a Swiss hospital	2
Current status of biosimilars in Turkey: A survey among medical oncologists	2
A practical method for oral administration of isotretinoin in pediatric oncology patient: A case study of neuroblastoma	2